Aspects of Endocrine Therapy in Primary Breast Cancer. Risk Profiling and Adherence Perspectives for Improving Tailored Adjuvant Treatment.
Abstract: Breast cancers are heterogeneous tumours. Prognostic markers are needed to better profile the patient´s risk, and predictive markers to indicate the expected benefit of systemic treatment. Using gene expression analyses, breast tumours can be divided into intrinsic subtypes. Immunohistochemical (IHC) markers (oestrogen and progesterone receptors (ER and PR), human epidermal growth factor
